Pediatric Myopia Progression Slowed by Low-Dose Atropine
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, June 6, 2023 -- Low-dose atropine treatment reduces pediatric myopia progression compared with placebo over three years of treatment, according to a study published online June 1 in JAMA Ophthalmology.
Karla Zadnik, O.D., Ph.D., from The Ohio State University in Columbus, and colleagues assessed the safety and efficacy of NVK002, a novel, preservative-free, once-daily 0.01 percent and 0.02 percent low-dose atropine formulation for treating myopia progression versus placebo. The analysis included 573 randomly assigned pediatric participants (aged 3 to 10 years in the safety group, of whom 489 children aged 6 to 10 years were in the modified intention-to-treat group), from 23 sites in North America and five countries in Europe. Participants had −0.50 diopter (D) to −6.00 D spherical equivalent refractive error (SER) and no worse than −1.50 D astigmatism.
The researchers found that compared with placebo, low-dose atropine (0.01 percent) significantly increased the responder proportion (odds ratio, 4.54; 95 percent confidence interval, 1.15 to 17.97; P = 0.03), slowed mean SER progression (least squares mean [LSM] difference, 0.24 D), and slowed axial elongation (LSM difference, −0.13 mm) at the three-year mark. While 0.02 percent dosage also showed benefit, it was not associated with a significant increase in the responder proportion (odds ratio, 1.77; 95 percent confidence interval, 0.50 to 6.26; P = 0.37) nor slowed mean SER progression (LSM difference, 0.10 D), but it did slow mean axial elongation (LSM difference, −0.08 mm). Atropine was not associated with any serious ocular adverse events.
"Trial results show that the efficacy and safety observed may be supportive of a pharmacological treatment option for myopia progression in children," the authors write.
Several authors disclosed ties to ophthalmic-biopharmaceutical companies, including Vyluma, which manufactures NVK002 and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Models Can Predict Long-Term Visual Acuity in Highly Myopic Eyes
TUESDAY, Oct. 31, 2023 -- For patients with high myopia, models for accurate prediction of the long-term visual acuity (VA) based on clinical and imaging information are feasible...
AI Model Can Respond Appropriately to Ophthalmology Questions
FRIDAY, Aug. 25, 2023 -- Large language models (LLMs) like ChatGPT can respond to patient-written ophthalmology questions and usually generate appropriate responses, according to...
Atropine 0.01 Percent Eye Drops Do Not Slow Myopia Progression
MONDAY, July 17, 2023 -- For children aged 5 to 12 years with low-to-moderate bilateral myopia, atropine 0.01 percent eye drops do not slow myopia progression over two years of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.